These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23924588)

  • 1. Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients.
    Rodríguez-Sáinz C; Valor L; Hernández DC; Gil J; Carbone J; Pascual-Bernaldez M; Rodríguez-Alcántara F; Martínez I; Vicario JL; Mallal S; Fernández-Cruz E
    HIV Clin Trials; 2013; 14(4):160-4. PubMed ID: 23924588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive evaluation of two HLA-B17 monoclonal antibodies for flow cytometry-based HLA-B57/B58 screening prior to abacavir prescription.
    Stevens R; Coates E; Street J; Cook E; Darke C
    Int J Immunogenet; 2013 Aug; 40(4):311-5. PubMed ID: 23280011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
    De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L
    PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 6. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External quality assessment of HLA-B*5701 reporting: an international multicentre survey.
    Hammond E; Almeida CA; Mamotte C; Nolan D; Phillips E; Schollaardt TA; Gill MJ; Angel JB; Neurath D; Li J; Giulivi T; McIntyre C; Koultchitski G; Wong B; Reis M; Rachlis A; Cole DE; Chew CB; Neifer S; Lalonde R; Roger M; Jeanneau A; Mallal S
    Antivir Ther; 2007; 12(7):1027-32. PubMed ID: 18018760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity.
    Kostenko L; Kjer-Nielsen L; Nicholson I; Hudson F; Lucas A; Foley B; Chen K; Lynch K; Nguyen J; Wu AH; Tait BD; Holdsworth R; Mallal S; Rossjohn J; Bharadwaj M; McCluskey J
    Tissue Antigens; 2011 Jul; 78(1):11-20. PubMed ID: 21501118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment.
    Chan J; Soraya GV; Craig L; Uddin SM; Todaro M; Huynh DH; Abeyrathne CD; Kostenko L; McCluskey J; Skafidas E; Kwan P
    Sensors (Basel); 2019 Aug; 19(16):. PubMed ID: 31416185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
    Poggi H; Vera A; Lagos M; Solari S; Rodríguez P L; Pérez CM
    Braz J Infect Dis; 2010; 14(5):510-2. PubMed ID: 21221482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain.
    Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M
    Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA
    Mounzer K; Hsu R; Fusco JS; Brunet L; Henegar CE; Vannappagari V; Stainsby CM; Shaefer MS; Ragone L; Fusco GP
    AIDS Res Ther; 2019 Jan; 16(1):1. PubMed ID: 30651100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.